Understanding Hepatitis: An Overview
What is Hepatitis?
Hepatitis is an infection that results in inflammation and damage to the liver. Its history dates back over 5,000 years, with early outbreaks recorded in China. The condition can be triggered by five distinct viruses from the hepatotropic family: hepatitis A, B, C, D, and E.
The Unique Nature of Hepatitis D
Hepatitis D, also known as delta hepatitis, is notable for being the smallest virus identified that can infect humans. Despite its size, it represents the most severe variant of hepatitis.
Transmission of Hepatitis D
How Infections Occur
Infection by the hepatitis D virus is only possible in the presence of the hepatitis B virus. Both viruses share similar modes of transmission, primarily occurring through contact with contaminated blood or bodily fluids. When a person is concurrently infected with both viruses, it is termed co-infection. If an individual with an existing hepatitis B infection is later exposed to hepatitis D, this results in a superinfection.
Risk Factors and Complications
Co-infection with hepatitis B and D can generally be cleared in healthy individuals. However, a superinfection poses greater risks, as it can quickly lead to cirrhosis and significantly heighten the likelihood of developing hepatocellular carcinoma, a type of liver cancer. Research indicates that hepatitis D infection doubles the risk of mortality from cirrhosis and triples the risk of hepatocellular carcinoma in patients already infected with hepatitis B.
Prevalence of Hepatitis D Infections
Geographic Distribution
Despite the reduction in hepatitis D infections due to hepatitis B vaccinations, regions with substandard socioeconomic and hygienic conditions continue to face challenges with viral hepatitis D. Countries in the Asia-Pacific area, including China, India, Nigeria, the Philippines, and Pakistan, report the highest prevalence rates of hepatitis D. Approximately 12 million people worldwide are estimated to be infected with the hepatitis D virus, with a ratio of one hepatitis D case for every 22 hepatitis B cases.
Treatment Options for Hepatitis D
Managing Infections
The outcomes for individuals infected with the hepatitis D virus can vary widely, ranging from asymptomatic cases to death from liver failure. Asymptomatic patients with normal liver enzyme levels typically do not require treatment, as co-infections can resolve on their own.
Interferon Therapy
For immunocompromised patients and those experiencing superinfections, interferon therapy remains the only effective treatment option. Interferons are substances naturally produced by the body that act as immunomodulators. This therapy has demonstrated efficacy in certain cases of hepatitis D, though not universally.
Interferon therapy was first proposed in the 1980s for its ability to halt hepatitis D viral replication. However, subsequent clinical trials revealed that only a subset of patients responds favorably to high doses administered frequently. Additionally, this therapy can lead to various side effects, including flu-like symptoms, fatigue, and weight loss.
The Need for New Interventions
Given the limitations of current treatment options, there is a pressing need for the development and evaluation of new therapeutic strategies to effectively manage hepatitis D infections.
References
1. Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol. 2021;27(16):1691-1715. doi:10.3748/wjg.v27.i16.1691
2. Miao Z, Xie Z, Ren L, Pan Q. Hepatitis D: advances and challenges. Chin Med J (Engl). 2022;135(7):767-773. doi:10.1097/cm9.0000000000002011
3. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat. 2005;12(1):2-9. doi:10.1111/j.1365-2893.2005.00601.x
4. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532. doi:10.1016/j.jhep.2020.04.008
5. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: Does it differ from hepatitis B monoinfection. Saudi J Gastroenterol. 2012;18(1):18-22. doi:10.4103/1319-3767.91731